Prevalence and Impact of Atrial Fibrillation in a Cohort of Patients with Hypertrophic Cardiomyopathy in Ireland

McClelland S, O’Connor SA, Donohue S, Lavelle L, McErlean A, Dodd JD, Meaney J, McCreery CJ, McDonald K, Quinn M, Erwin JE, Quigley PJ, Maurer B, Keane D

St. Vincent’s University Hospital, Elm Park, Dublin 4, Ireland.



Atrial fibrillation (AF) is the most common sustained arrhythmia in patients with hypertrophic cardiomyopathy (HCM), and is associated with deterioration in clinical status and outcome. To date, no data have been published pertaining to AF in an Irish HCM population.

Methods and Results:

159 patients with HCM attending St Vincent’s University Hospital and Blackrock Clinic, Dublin, were identified. Detailed review of medical notes, Holter monitor, echocardiogram, cardiac MRI (CMR) and implantable cardioverter-defibrillator (ICD) records was performed.

Prevalence of AF was 38.4%. HCM patients with AF (HCM-AF) were older (60.6±14.8 v 54.9±17.3 years, P=0.016) and more symptomatic (NYHA II: 29.7% v 16.9%, NYHA III: 4.3% v 1.2%) than HCM patients without AF. History of stroke was recorded in 16.4% of HCM-AF patients, compared with 1% in those without AF.

HCM-AF patients had lower left ventricular ejection fraction (echo: 59.5±11.8v68±8, P<0.001; CMR: 62.3%v70.5%, P<0.01) and higher left atrial diameter (echo: 49.8±9.5v40.9±7.4, p<0.001; CMR 62.3±11.3v70.4±9, p<0.001), compared with those without AF. Myocardial fibrosis was detected on CMR in 74% of HCM-AF patients and 62% of those without AF.

34% of patients had an ICD in situ, of whom 61% had AF. 24% of these HCM-AF patients received inappropriate shocks, all triggered by AF.


AF is common in the Irish HCM population. It is associated with increased risk of stroke, deterioration in symptom status and is a common trigger for inappropriate ICD discharge. We have shown, in-keeping with previous studies, that AF is associated with reduced EF, increased LA diameter and mitral regurgitation in this HCM population.

Key Words : Hypertrophic Cardiomyopathy, Atrial fibrillation, Left Atrium, Cardiac MRI.

Sarah McClelland, St. Vincent’s University Healthcare Group, Dublin, Ireland.


Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiovascular disorder, with a reported prevalence of 1 in 500 in the general population1, and is a leading cause of sudden death in young people2,1,3. HCM is characterised by significant heterogeneity in terms of causative genetic mutations and phenotypic expression. Consequently, HCM populations internationally may differ significantly in terms of their clinical characteristics and outcomes. In Ireland, HCM was the most common cause of sudden cardiac death (SCD) in patients younger than 25 years in the 10 years between 1993 and 20024 and the third most common cause of SCD in patients aged between 15 and 35 years, from 2005 to 20075.

Atrial fibrillation (AF) is the most common sustained arrhythmia and clinical complication in patients with HCM6, and its development is characterised by deterioration in clinical status, functional capacity, quality of life and outcome1, 7-9. The unfavourable prognosis in HCM patients with AF is secondary to the resultant increased risk of heart failure-related mortality, thromboembolism, and severe functional impairment10. AF has been reported to be present in approximately 5% of HCM patients at the time of diagnosis, with an annual incidence of 2% per year, almost 5-times that of the general population8. Indeed, the true annual incidence of AF may be higher, with a recent study demonstrating a 7% annual incidence of device-detected AF in patients with implantable cardiac devices11 A number of factors have been identified that predict susceptibility to AF in the HCM population. These include advancing age12, left atrial enlargement1, 13, 14, mitral regurgitation severity, and the presence and extent of myocardial fibrosis13, 15. however not all studies have concurred.

The overall prevalence of AF in HCM patients has been reported to be 22%16, from systematic review of the literature, however, the prevalence within reported populations internationally varies widely, ranging from 18-35%16. This is unsurprising given the marked genetic and phenotypic heterogeneity that characterises HCM. For this reason, it is important to determine local characteristics of HCM populations, to identify areas for risk reduction and therapeutic intervention

To date, no data has been published relating to AF in a HCM population in Ireland. Here, we report on the clinical and imaging characteristics of a cohort of HCM patients in Ireland, as well as the prevalence and impact of AF in this Irish HCM population.


Patient Identification:

A cohort of 159 adult patients with HCM attending St Vincent’s University Hospital, and Blackrock Clinic, Dublin, was identified via electronic radiology and echocardiography reports, clinical letters, and chart review.

Clinical Evaluation:

Clinical information pertaining to symptom status, family history, risk factors for SCD and current medications was collected by detailed review of medical notes and out-patient letters. Information on the presence or absence of AF, sustained or non-sustained ventricular tachycardia, or other arrhythmia, was obtained by review of Holter monitor reports, medical notes, ECGs, and pacemaker/ICD interrogation reports. The occurrence of appropriate or inappropriate ICD discharge was established based on ICD interrogation reports and review of medical notes.

Imaging characteristics were obtained from transthoracic echocardiogram (TTE) and cardiac MRI (CMR) reports.

Details were recorded at a single time-point for each patient, reflecting the most recent clinical and imaging details at the time of investigation. In those cases where clinical or imaging data were incomplete, these patients were omitted from analysis of the affected parameters.


Echocardiographic measurements were made on TTE in the standard views, as per the European Society of Echocardiography guidelines. Left ventricular hypertrophy was assessed on TTE in the parasternal short-axis view at end diastole, at the mitral valve and papillary muscle levels. Left ventricular end-diastolic diameter (LVEDD) and end-systolic diameter (LVESD) were measured from parasternal long-axis views. The left ventricular outflow tract (LVOT) gradient was calculated from continuous-wave Doppler using the simplified Bernoulli equation.

Cardiac MRI:

All subjects were examined on a 1.5 Tesla magnet (Avanto, Siemens, Erlangen, Germany) using an eight-element phased-array cardiac coil for signal reception. Left and right ventricular function was obtained with single slice cine images using a steady-state free precession (SSFP) technique (repetition time, 3.5msec; echo time, 1.4msec; matrix, 192x192; field of view, 34x34 cm; slice thickness 6mm, slice gap 1mm) obtained in two-chamber, four-chamber and short axis planes to include the entire ventricle from base to apex. These were followed by a bolus injection of 0.2 mmol/Kg of hand-injected gadopentetate dimeglumine (Gd-DTPA - Schering AG, Berlin, Germany). Between 10 -12 minutes later, LE CMR was obtained by using single slice double inversion-recovery prepared gated fast-gradient echo pulse sequences. Late enhancement images were acquired to optimally show normal myocardium/trabeculae (dark) and regions of LE within myocardium (bright) with proper selection of the inversion time (TI). Imaging parameters were as follows: TR 7.1ms; TE 3.1ms; image matrix 256x192; flip angle 20o; inversion pulse 180o; slice thickness 7, slice gap 1mm, and TI between 150 and 300ms.

Data Analysis:

Data are expressed as mean +/- standard deviation or frequency (percentage), as appropriate. Differences in continuous variables with normal distribution were assessed using the two-sample t-test. Categorical variables are expressed as percentages and were compared using the Fisher’s exact test. Statistical significance was defined by P<=0.05.

Ethical Approval:

Approval was granted from the clinical research and audit committee, St. Vincent’s University Hospital.


Patient demographics:

A total of 159 patients with HCM were identified for whom rhythm and imaging data were available. Of these, 99 (62.3%) were male. The median age was 59 years, with a range from 17-90 years. There was a documented family history of HCM in 30.2% of cases. [Table 1].

Clinical Characteristics at Registration:

The clinical characteristics and risk factors for SCD in the HCM population are listed in [Table 1]. 27.7% of patients were known to have had one or more episodes of sustained or non-sustained ventricular tachycardia. 11.3% had one or more episodes of syncope, while a family history of SCD was present in 20.8% of cases. Eight patients (5%) had LV wall thickness of >30mm. Of the 73 patients with exercise stress test results documented, 9 (12.3%) had a hypotensive response to exercise. One patient (0.6%) had survived a previous cardiac arrest.

Prevalence and complications of Atrial Fibrillation:

Atrial fibrillation was documented in 61 patients (38.4%) in this HCM population. Patients with documented AF were significantly older than those without AF (mean age 60.6 +/-14.8 v 54.9+/-17.3 years, P=0.016), and there was a male preponderance in the AF group (63.9%). 28% of the HCM patients with AF were aged 50 years or younger.

New York Heart Association (NYHA) functional class was documented for 131 patients (47 AF, 83 non-AF). Patients with AF were more likely to be symptomatic than those HCM patients in sinus rhythm. The proportion of patients reporting NYHA I symptoms was significantly higher in HCM patients without AF, compared with those with AF (80.7% vs 64.6%, p<0.05) , with 29.8% and 4.2% of AF patients in NYHA Class II or III, respectively, compared 16.9% and 1.2% of patients without AF. [Figure 1].

Figure 1. Symptom status in HCM patients with and without atrial fibrillation:

33.4% of HCM-AF patients were in NYHA functional class II or III, compared with 18.1% of Non-AF HCM patients. Data are expressed as percentage (%) of HCM population in each symptom class.

The overall prevalence of thromboembolism in HCM patients with AF in published cohorts is 27%, with a range from 19-58%16. In this HCM cohort, a total of 17 patients were documented to have experienced CVA and/or TIA. CVA occurred in 11 patients (6.9%), and transient ischaemic attack (TIA) occurred in 10 patients (6.3%). 91% of the patients who experienced CVA, and 70% of the patients with previous TIA had documented AF. Stroke had occurred in 18% of HCM patients with AF in this cohort. The overall prevalence of CVA/TIA in this HCM-AF cohort was 27.8%. [Table 1].

Medications in use at the time of index review were known for 145 patients [Table 1]. The most frequently used medications were beta-blockers (70.3%), statins (66.2%) and antiplatelet agents (33.7%). 39 patients with AF (67.3%) were taking an oral anticoagulant (OAC) at the time of index review which was significantly lower than expected, while a further 2 patients with AF had stopped OAC due to bleeding complications.

Imaging Characteristics in HCM patients with and without AF:

All patients had baseline imaging performed by means of standard transthoracic echocardiography (TTE, n=152) or cardiac MRI (CMR, n=109), or both. Imaging characteristics were recorded for each patient, and are presented in [Table 2].

Table 2. Imaging characteristics in HCM patients as assessed by echocardiography and cardiac MRI
All patients Patients with AF Patients without AF P-Value
Echocardiographic Characteristics (n=152)) Echocardiographic Characteristics (n=152)) (n=57) (N=95)
Ejection Fraction (%) 64.6±10.5 59.5±11.8 68±8 <0.001
LA diameter, mm 44.3±9.3 49.8±9.5 40.9±7.4 <0.001
LV end-diastolic dimension, mm 47±6.6 48.1±6.8 46.4±6.3 0.08
LV end-systolic dimension, mm 29.2±6.5 31.63±7.9 27.7±5 <0.001
Interventricular septal diameter, mm 18.2±6 18.3±5.6 18.2±6.3 0.46
Posterior Wall Thickness, mm 12.5±2.8 12±3.3 12.8±2.5 0.14
Systolic Anterior Motion of MV (TTE or MRI) 26.7% 15 (n=61) (24.5%) 29 of 98 (29.6%) 0.59
LVOT > 30mmHg 29 (18.2%) 11 (18%) 18 (18.4%) 1.0
Moderate to severe MR (TTE or MRI) 19 (11.9%) 12 (19.7%) 7 (7.1%) <0.0001
Cardiac MRI Characteristics (n=93)
Ejection Fraction (%) 69.9+/-10.4 62.3±11.3 70.4±9 <0.001
Max Thickness, mm 18.2±6 19.7±1.07 19.48±0.85 0.17
LA diameter, mm 37.8±8 42.7±9.4 35.3±6.5 <0.001
End diastolic dimension, mm 49.41±5.5 48.3±5.9 49.8±5.3 0.17
End systolic dimension, mm 27.83±7.4 27.5±8.4 28±7.1 0.41
Anterior septal wall thickness, mm 18.1±6 19.2±4.8 17.7±6.5 0.17
Posterior septal wall thickness, mm 8.8±3.2 8.6±3.9 8.8±3 0.37
Late Gadolinium Enhancement (%) 72 (n=109,66%) 28 (n=38, 73.7%) 44(n=71, 62%) 0.29

LA, left atrial; LV, left ventricular; MV, mitral valve; TTE transthoracic echocardiogram; MRI, magnetic resonance imaging;

HCM tends to be a hyperdynamic state, usually resulting in supra-normal left ventricular ejection fraction (LVEF). In the HCM group as a whole, the average LVEF measured on TTE was 64.6±10.5%, and measured by CMR was 69.9+-10.5%. There was a statistically significant reduction in LVEF in HCM patients with AF compared with those in sinus rhythm, as measured by TTE (59.5±11.8% vs 68±8%, P<0.001) and CMR (62.3±11.3% vs 70.4±9%, p<0.001) ([Table 2] and [Figure 2]).

Figure 2. Imaging characteristics of HCM patients with and without atrial fibrillation.

Assessment of LVEF by TTE; B. Assessment of LVEF by CMR; C. Comparison of chamber dimension and LV wall thickness assessed by TTE; D. Comparison of chamber dimension and LV wall thickness assessed by CMR. **p<0.001

Left atrial (LA) diameter was measured by TTE and CMR. In the group as a whole, the average LA diameter was 44.3±9.4mm, measured by TTE, and 37.6±8mm measured by CMR. As expected, LA diameter was significantly increased in HCM patients with AF compared with those without AF, as assessed by TTE (49.3+/-9.5mm vs 40.9+/-7.4mm, P<0.001) and CMR (42.7+/-9.4mm vs 35.3+/-6.5mm, P<0.001). 61.2% of patients with AF had moderately or severely dilated LA on TTE, while moderate to severe LA dilatation was present in 22.8% of HCM patients without AF (p<0.0001).

Left ventricular end diastolic dimension (LVEDD) and left ventricular end systolic dimension (LVESD), as assessed by TTE, in the HCM group as a whole were 47±6.6mm and 29.2±6.5mm, respectively. There was a trend towards larger LVEDD in the AF group that did not reach statistical significance (48.1+/-6.8mm vs 46.4+/-6.6mm, p=0.08), and there was a significant increase in LVESD in the AF group compared with those without AF (31.6+/-7.9 vs 27.7+/-5mm, p<0.001), as measured by TTE, which may reflect the progression towards the dilated phase in those HCM patients with AF. However, this change in LV dimensions was not observed in those patients who underwent CMR (LVEDD 48.3+/-5.8mm vs 49.2+/-6mm, P=0.3; LVESD 27.5+/-8.4mm vs 28.1+/-7.7mm, P=0.3). [Figure 2]. This may be explained by the use of TTE as primary imaging modality in patients with implantable cardiac devices in situ.

The overall maximal LV wall thickness in the HCM cohort was measured by TTE at 18.2±6mm, and at 18.1±6.1mm by CMR. There was no significant difference in the degree of septal hypertrophy in the AF group compared with those patients without AF, as measured by TTE or CMR (18.3±05.6mm vs 18.2±6.3mm, p=0.46; and 19.2±4.8mm vs 17.5±6.5mm, p=0.16). [Figure 2]

Myocardial fibrosis was detected in 66% (72 patients) of the HCM patients who underwent CMR in this cohort (n=109). There was a higher prevalence of myocardial fibrosis in HCM population with AF than those without AF (73.7% vs 61.9%), however this did not reach statistical significance. Similarly, there was no significant difference in the severity of LGE between the two groups.

ICD Discharge Events:

54 (33.5%) of the HCM patients studied had an ICD in situ, 61% of whom had AF. Of those HCM-AF patients with ICDs in situ, 24% received inappropriate shocks, all of which were triggered by AF, while 9.1% received appropriate ICD shocks [Table 1].

Table 1. Clinical characteristics of HCM patients with and without AF at index review.
All patients (n=159) Patients with AF (n=61) Patients without AF (98) P-Value
Age at registration, years (mean, range) 59 (17-90) 61 (21-90) 57.5 (17-90) 0.016
Gender: male (%) 99 (62.3%) 39 (63.9%) 60 (60.6%) 0.738
Family history HCM 48 (30.2%) 14 (23%) 34 (34.7%) 0.155
Atrial fibrillation 61 (38.4%)
Risk factors for SCD
NSVT 44 (27.7%) 23 (37.7%) 21 (21.4%) 0.74
Syncope 18 (11.3%) 10 (16.4%) 8 (8.1%) 0.128
Family history SCD 33 (20.8%) 10 (16.4%) 23 (23.5%) 0.32
LV>30mm 8 (5%)
Hypotensive response to exercise (n=73) 9 (12.3%) 3 (15.8%, n=19) 6 (11.1%, n=54) 0.688
Aborted SCD 1 (0.6%) 1 (1.6%) 0 0.384
LVOT grad >30mmHg 29 (18.2%) 11 (18%) 18 (18.4%) 1.0
Symptoms at index review (n=143) (n=53) (n=90)
Chest Pain 23( 16.1%) 5 (9.4%) 18 (20%) 0.11
Palpitations 36 (25.2%) 19 (35.8%) 17 (18.9%) 0.03
Pre-syncope 13 (9.1%) 4 (7.5%) 9 (10%) 0.77
NYHA Class (n=131) (n=48) (n=83)
I 99 (75.6%) 31 (64.6%) 67 (80.7%) 0.036
II 28 (21.4%) 14( 29.2%) 14 (16.9%) 0.12
III 4 (3.1%) 3 (4.2%) 1 (1.2%) 0.14
IV 0 0 0
History of stroke 11 (6.9%) 10 (16.4%) 1 (1.0%) 0.0003
History of TIA 10 (6.3%) 7 (11.5%) 3 (3,1%) 0.044
ICD implantation 54 (33.9%) 33 (54.1%) 21 (21.4%) 0.0001
Appropriate ICD shock(s) 4 2 (6.1%) 2 (9.5%) 0.64
Inappropriate ICD shock(s) 11 8 (24.2%) 3 (14.3%) 0.49
Medications (n=145) (n=58) (n=87)
Beta-blocker 102 (70.3%) 41 (70.7%) 61 (70.1%) 0.61
Statin 96 (66.2%) 24 (41.4%) 51 (58.6%) 0.14
Aspirin 44 (30.3%) 16 (27.6%) 28 (32.2%) 0.56
ACE/ARB 40 (27.6%) 17 (29.3%) 23 (26.4%) 0.58
CCB 31 (21.4%) 15 (25.9%) 16 (18.4%) 0.22
OAC 40 (27.6%) 39 (67.2%) 1 (1.1%) 0.0001
Sotalol 13 (9%) 9 (15.5%) 4 (4.6%) 0.07
Amiodarone 10 (6.9%) 8 (13.8%) 2 (2.3%) 0.007
Frusemide 10 (6.9%) 6 (10.3%) 4 (4.6%) 0.18
Clopidogrel 5 (3.4%) 1 (1.7%) 4 (4.6%) 0.65
Digoxin 3 (2.1%) 3 (5.2%) 0 0.05

HCM, hypertrophic cardiomyopathy; SCD, sudden cardiac death; NSVT, non-sustained ventricular tachycardia; NYHA, New York heart association); TIA, transient ischaemic attack; ICD, implantable cardioverter defibrillator; ACE, angiotensin converting enzyme; ARB, angiotensin receptor blocker; CCB, calcium channel blocker; OAC, oral anticoagulant


The maintenance of sinus rhythm is crucial for the functional capacity of patients with HCM17. AF is the most common sustained arrhythmia affecting patients with HCM. Its development is associated with clinical and functional deterioration, as well as increased risk of embolic stroke and heart-failure progression18. While AF is not an independent determinant of SCD, there is a 3-fold increase in the risk of HCM-related deaths in AF patients compared with that in matched controls in sinus rhythm8. There is significant heterogeneity within HCM populations, in terms of genetic and phenotypic characteristics. Unsurprisingly, therefore, the prevalence of AF in internationally reported cohorts has varied widely16. Determination of the local characteristics of HCM populations is important, therefore, in order to identify areas for risk reduction and opportunities for therapeutic intervention. Herein we have determined the prevalence of AF in an Irish HCM population to be 38%. This is a relatively high proportion compared with international studies, however, it is similar to that reported in the UK (30%)6. The high prevalence of AF in this HCM population underscores the necessity for close monitoring and early pharmacological intervention to minimise embolic complications in our HCM population.

The Irish population has been shown to be genetically homogeneous. 28, 29, which is reflected the higher frequencies of several traits, including cystic fibrosis, galactosaemia, multpiple sclerosis, and lactase deficiency, compared to those of mainland Europe 29. This genetic homogeneity lends itself well to the study of inherited diseases, and may in part underlie the relatively higher incidence of atrial fibrillation in this cohort, compared with other published cohorts. Conversely, however, these findings may not be directly applicable to poplulations with wider genetic diversity, such as that of the United States of America.

In this cohort, HCM patients with AF were significantly older than those without documented AF, in keeping with previous studies12. Unsurprisingly, the presence of AF is correlated with increasing symptom severity, with fewer HCM-AF patients reporting NYHA class I symptoms than those without documented AF. This finding is in-keeping with those of other large HCM cohorts19, and underscores the link between the development of AF and deterioration of functional status.

HCM patients with AF have been shown to have an 8-fold increase in the risk of ischaemic stroke compared with that of HCM patients in sinus rhythm.8 The prevalence of cardioembolic complications in our HCM-AF population (27.9%) was very similar to the overall prevalence reported by Guttmann et al. (27%)16. While all but one stroke occurred in patients with known AF, 30% of those experiencing a TIA did not have documented AF. This raises the important question as to whether these patients are experiencing undiagnosed paroxysmal AF, and warrant more frequent or more lengthy rhythm monitoring.

There are currently no randomised controlled clinical trials addressing the use of anticoagulation in HCM patients, and the CHA2DS2-VASc score is not validated in this patient group. However, the relatively high rate of cardioembolic complications in HCM patients with AF has led to the general consensus that all patients with HCM and paroxysmal or persistent AF be anticoagulated20, 21, even following the restoration of sinus rhythm. 70.6% of patients in this HCM-AF population had a history of OAC use, while 67% of HCM-AF patients were anticoagulated at the time of data recording. This was a lower proportion of patients than expected, and warrants further investigation.

HCM is a hyper dynamic state, with frequently supra-normal left ventricular ejection fraction (EF) demonstrated. In this cohort, left ventricular function was significantly reduced in the HCM-AF group, compared to those patients in sinus rhythm, as measured by echocardiography and CMR, in keeping with the findings in other international HCM-AF cohorts19.

Left atrial (LA) size, volume and function have been shown to be determinants of AF in HCM patients8, 13, 17, 22. It has been suggested that the strong relationship between LA dilatation and AF in HCM patients may be explained by the electrical and structural remodelling that occur in the process of LA dilatation, including shortening of the atrial effective refractory period and local conduction delay13. Indeed, an upper LA size of 4.5cm has been proposed in recent ESC guidelines, beyond which more frequent rhythm monitoring should be performed due to the increased risk of developing AF21. Here, we have confirmed the association of LA size with AF in this Irish HCM population. As expected, LA diameter was significantly increased in our HCM patients with AF compared with those without AF, as assessed by echocardiography and CMR. The severity of mitral regurgitation has also been shown previously to correlate with the presence of AF in HCM patients. This association is also reflected in the data from this cohort, where moderate to severe MR was present in 19.7% of HCM patients with AF, compared with 7.1% of those without documented AF. Furthermore, in keeping with the observation from numerous international studies that there is no association between outflow tract obstruction and AF19, we did not observe increased rates of AF in patients with significant outflow tract obstruction.

The presence and extent of myocardial fibrosis, as demonstrated by late gadolinium enhancement (LGE) on CMR has been shown to correlate with poor prognosis in HCM patients23, and to be independently associated with AF24, as well as sustained ventricular tachycardia and appropriate ICD discharges25 in patients with HCM. LGE is inferior to LA size for predicting AF prevalence, however. It has been suggested that the extent, but not the presence, of myocardial fibrosis is indicative of AF in HCM patients13, the severity of myocardial fibrosis on CMR has been shown to predict sustained arrhythmic events in HCM patients25. In this cohort, there was a higher prevalence of LGE in the HCM-AF group, however this did not reach statistical significance.

Implantable cardioverter defibrillators (ICD) successfully terminate life-threatening arrhythmias in HCM patients at increased risk of SCD. ICD insertion is indicated in HCM patients with significant or numerous risk factors for SCD, or who have had a resuscitated cardiac arrest20. In HCM patients with ICDs, end-stage heart failure is the leading cause of mortality26. Rapidly conducted AF and other SVTs have been shown to account for up to 80% of unnecessary shocks in patients with ICDs27. 34% of the patients in this HCM population had an ICD in situ. Of those patients for whom ICD interrogation data was available, 27.8% (15 patients) had received an ICD shock, the majority of which were inappropriate [Table 1]. Almost a quarter of of HCM-AF patients with ICDs had received an inappropriate shock(s), all of which were triggered by AF, illustrating a further complication arising from AF in in this HCM cohort.


While this study is the first on clinical and imaging characteristics in an Irish HCM population, it has a number of limitations. The data for each patient is retrospective and represents a single time point, and does not take into account duration of diagnosis or response to treatment. Furthermore, the data is limited to a clinical history of stroke and it might be postulated that a prospective study of routine brain MRI screening may reveal additional silent ischaemic events. Routine genetic analysis was not performed in this study and thus it is unknown if the relatively high incidence of AF in our study could reflect a unique genetic preponderance in this Irish HCM cohort.

Further prospective studies of outcome, response to definitive AF treatment strategies, prognosis and prognostic factors in patients with AF and HCM are planned.


We have demonstrated that AF is common in the Irish HCM population, with a prevalence of 38.4%. It is associated with increased risk of stroke, deterioration in symptom status and inappropriate ICD discharge. We have also shown, in-keeping with international registries, that AF is associated with reduced EF, increased LA diameter and mitral regurgitation, in an Irish HCM population.


  • [ PubMed ]
  • [ PubMed ]
  • [ PubMed ]
  • [ PubMed ]
  • [ PubMed ]
  • [ PubMed ]
  • [ PubMed ]
  • [ PubMed ]
  • [ PubMed ]
  • [ PubMed ]
  • [ PubMed ]
  • [ PubMed ]
  • [ PubMed ]
  • [ PubMed ]
  • [ PubMed ]
  • [ PubMed ]
  • [ PubMed ]
  • [ PubMed ]
  • [ PubMed ]
  • [ PubMed ]
  • [ PubMed ]
  • [ PubMed ]
  • [ PubMed ]
  • [ PubMed ]
  • [ PubMed ]
  • [ PubMed ]
  • [ PubMed ]